[ad_1]
Synopsis
Krsnaa Diagnostics’ IPO was oversubscribed 64.4x, second only to Thyrocare’s 73x. It has caught the fancy of retail investors. The company’s differentiated model — a strong presence in radiology, in-hospital centres, and government contracts — sets it apart from its peers. Does Krsnaa have the potential to become a multi-bagger?
The diagnostics space has been seeing a lot of action since the Covid-19 outbreak. Shares of listed firms such as Dr Lal PathLabs, Metropolis Healthcare, and Thyrocare Technologies have surged between 160% and 200% so far since March 2020. There is now a greater realisation about the importance of diagnostics in preventing and managing diseases. This is a big positive for the industry, which is still largely fragmented and under-penetrated in
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Get Offer
Why ?
-
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link